Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Generex Biotechnology Corp. (GNBTQ) had Revenue of $2.66M for the most recently reported fiscal year, ending 2020-07-31.

Quarterly Annual

Figures for fiscal year ending 2020-07-31

Income Statement Financials
Revenue	$2.66M
Net Income	$-33.34M
Cost of Goods Sold	$0.58M
Gross Profit	$2.08M
Operating Expenses	$20.60M
Operating Income	$-17.94M
Non-Operating Income/Expense	$-16.29M
Pre-Tax Income	$-34.23M
Normalized Pre-Tax Income	$-34.23M
Income after Taxes	$-34.23M
Income from Continuous Operations	$-34.23M
Consolidated Net Income/Loss	$-34.23M
Normalized Income after Taxes	$-34.23M
EBIT	$-17.94M
EBITDA	$-8.28M
Weighted-Average Shares Outstanding (Basic)	73.11M
Weighted-Average Shares Outstanding (Diluted)	73.11M
Earnings per Share (EPS) (Basic)	$-0.46
Earnings per Share (EPS) (Diluted)	$-0.46
Balance Sheet Financials
Current Assets	$1.25M
Property, Plant, and Equipment	$0.21M
Long-Term Assets	$44.13M
Total Assets	$45.38M
Current Liabilities	$41.37M
Long-Term Debt	$0.50M
Long-Term Liabilities	$11.90M
Total Liabilities	$53.27M
Common Equity	$-7.88M
Tangible Shareholders Equity	$-51.74M
Shareholders Equity	$-7.88M
Common Shares Outstanding	82.25M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-6.12M
Cash Flow from Investing Activities	$0.04M
Cash Flow from Financial Activities	$5.81M
Beginning Cash	$0.30M
End Cash	$0.02M
Increase/Decrease in Cash	$-0.28M
Stock-Based Compensation	$2.40M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	0.03
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	-0.07
Debt to Equity Ratio	-1.42
Gross Margin	78.21%
Operating Margin	-673.98%
EBIT Margin	-673.98%
EBITDA Margin	-311.07%
Pre-Tax Profit Margin	-1286.25%
Profit Margin	-1252.54%
Free Cash Flow	$-6.13M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.06
Inventory Turnover	0.78
Receiveable Turnover	16.14
Days Sales in Receivables	22.61
Return on Equity	434.18%
Return on Tangible Equity	66.16%
Return on Assets	-75.43%
Return on Investments	463.55%
Book Value Per Share	$-0.10
Free Cash Flow per Share	$-0.08
Operating Cash Flow per Share	$-0.08

Data from Zacks Investment Research, Inc.